Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $27.84 USD
Change Today +0.67 / 2.47%
Volume 2.2M
As of 8:10 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

celldex therapeutics inc (CLDX) Snapshot

Open
$27.82
Previous Close
$27.17
Day High
$29.20
Day Low
$27.51
52 Week High
03/19/15 - $32.82
52 Week Low
05/9/14 - $10.76
Market Cap
2.7B
Average Volume 10 Days
2.5M
EPS TTM
$-1.32
Shares Outstanding
96.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELLDEX THERAPEUTICS INC (CLDX)

celldex therapeutics inc (CLDX) Related Bloomberg News

View More Bloomberg News

celldex therapeutics inc (CLDX) Related Businessweek News

No Related Businessweek News Found

celldex therapeutics inc (CLDX) Details

Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The company’s lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, as well as in Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate in a randomized Phase IIb study for the treatment of triple negative breast cancer, as well as in Phase II study for the treatment of metastatic melanoma. It also has various earlier stage drug candidates in clinical development, including varlilumab (CDX-1127), a fully human therapeutic monoclonal antibody for cancer indications; CDX-1401, a targeted immunotherapeutic aimed at antigen presenting cells for cancer indications; and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. The company’s preclinical product candidate includes CDX-014, a fully-human monoclonal antibody-drug conjugate that targets T-cell TIM-1, a molecule, which is upregulated in various cancers comprising renal cell and ovarian carcinomas. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Alteris Therapeutics, Inc.; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc., as well as clinical trial collaboration with Roche Holding, Bristol-Myers Squibb Company, and Oncothyreon Inc. The company is headquartered in Hampton, New Jersey.

156 Employees
Last Reported Date: 02/24/15

celldex therapeutics inc (CLDX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $871.4K
Founder, Chief Scientific Officer and Executi...
Total Annual Compensation: $553.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $437.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $589.4K
Chief Business Officer and Senior Vice Presid...
Total Annual Compensation: $411.7K
Compensation as of Fiscal Year 2013.

celldex therapeutics inc (CLDX) Key Developments

Celldex Therapeutics Enters into Clinical Trial Collaboration with Roche Holding to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Renal Cell Carcinoma Treatment

Celldex Therapeutics has entered into a clinical trial collaboration with Roche Holding to evaluate the safety, tolerability and preliminary efficacy of a renal cell carcinoma treatment. The clinical trial will test varlilumab, Celldex's CD27 targeting investigational antibody, and MPDL3280A, Roche's investigational cancer immunotherapy in a Phase 1/2 study. Preclinical data suggest the combination of these two mechanisms are synergistic and may enhance anti-tumor immune response compared to either agent alone. Roche will provide study drug and Celldex will be responsible for conducting and funding the study, which is expected to begin in 2015. Varlilumab and MPDL3280A are part of a new class of investigational medicines known as cancer immunotherapies designed to use the body's own immune system to fight cancer through separate but complementary mechanisms of action that may enable the activation of T cells, restoring their ability to effectively detect and attack tumor cells.

Celldex Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Capital Expenditure Guidance for the Full Year 2016

Celldex Therapeutics, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company’s total revenue was $1.5 million compared to $0.6 million for the comparable periods in 2013. The increase in the fourth quarter of 2014 was primarily due to the company’s clinical trial collaboration with BMS and the company’s Rockefeller University services agreement. Net loss was $31.8 million, or $0.36 per basic and diluted share, compared to a net loss of $22.1 million, or $0.27 per basic and diluted share for the comparable periods in 2013. Operating loss was $32,051,000 compared to $22,114,000 a year ago. For the twelve months, the company’s total revenue was $3.6 million, compared to $4.1 million for the comparable periods in 2013. The decrease in the twelve months ended December 31, 2014 was primarily due to the decrease in Rotarix royalty revenue. Net loss was $118.1 million, or $1.32 per basic and diluted share, compared to a net loss of $81.6 million, or $1.02 per basic and diluted share for the comparable periods in 2013. Operating loss was $122,430,000 compared to $81,442,000 a year ago. The company provided capital expenditure guidance for the full year 2016. The company expects that its cash, cash equivalents and marketable securities will be sufficient to fund the company’s operating expenses and capital expenditure requirements through 2016, however, this could be impacted by the company’s clinical data results from the Rintega program and their potential impact on the company's pace of commercial manufacturing and the rate of expansion of the company’s commercial operations.

Celldex Therapeutics, Inc. Receives FDA Breakthrough Therapy Designation for the Treatment of Adult Patients with EGFRvIII-Positive Glioblastoma

Celldex Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted rindopepimut (Rintega Breakthrough Therapy Designation for the treatment of adult patients with EGFRvIII-positive glioblastoma (GBM). This application was based on data from the Phase 2 ReACT study in recurrent GBM, the Phase 2 ACT III study in newly diagnosed GBM and additional supportive Phase 2 studies. An international Phase 3 study of rindopepimut, called ACT IV, in newly diagnosed GBM completed enrollment (n=745) in December of 2014. Breakthrough Therapy Designation is intended to expedite the development and review of drugs for serious or life-threatening conditions. The criteria for Breakthrough Therapy Designation require preliminary clinical evidence that demonstrates the drug may have substantial improvement on at least one clinically significant endpoint over available therapy. Rindopepimut (Rintega) is an investigational immunotherapy that targets the tumor specific oncogene EGFRvIII. Patients with EGFRvIII-positive glioblastoma typically have a worse prognosis than the overall glioblastoma population, including poor long term survival. Rindopepimut (Rintega is an investigational immunotherapy that targets the tumor specific oncogene EGFRvIII (v3), a functional and permanently activated variant of the epidermal growth factor receptor (EGFR), a protein that has been well validated as a target for cancer therapy. Expression of EGFRvIII correlates with increased tumorigenicity in mouse models and poor long term survival in clinical studies of patients with glioblastoma (GBM). In addition, EGFRvIII-positive cells are believed to stimulate proliferation of non-EGFRvIII cells through IL-6 cell-to-cell signaling and to release microvesicles containing EGFRvIII, which can merge with neighboring cells, transferring tumor-promoting activity. EGFRvIII expression may also be associated with tumor stem cells that have been identified in GBM. These stem cells contribute to resistance to cytotoxic therapy and tumor recurrence. EGFRvIII is expressed in tumors in about 30% of patients with GBM. It has not been detected at a significant level in normal tissues; therefore, targeting of this tumor-specific molecule is not likely to impact healthy tissues. Three Phase 2 trials of rindopepimut, ACTIVATE, ACT II, and ACT III, have been completed in newly diagnosed EGFRvIII-positive GBM and have shown consistent improvements in both overall survival and median progression-free survival. The most common adverse events for rindopepimut include injection site reactions, fatigue, rash, nausea and pruritus. Rindopepimut is currently being studied in two clinical trials in EGFRvIII-positive GBM ”an international Phase 3 study called ACT IV in newly diagnosed GBM and a Phase 2 study called ReACT in recurrent GBM.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLDX:US $27.84 USD +0.67

CLDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLDX.
View Industry Companies
 

Industry Analysis

CLDX

Industry Average

Valuation CLDX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLDEX THERAPEUTICS INC, please visit www.celldextherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.